Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
To assess the antitumor activity of lurbinectedin (PM01183) in terms of overall response rate (ORR), according to the Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1, in the following advanced solid tumors: small cell lung cancer (SCLC), head and neck
carcinoma (H&N), neuroendocrine tumors (NETs), biliary tract carcinoma, endometrial carcinoma, BRCA 1/2-associated metastatic breast carcinoma, carcinoma of unknown primary site, germ cell tumors (GCTs), and Ewing¿s family of tumors (EFTs).
To further characterize the antitumor activity of PM01183 in terms of duration of response (DR), clinical benefit [ORR or stable disease (SD) lasting over four months (SD ¿ 4 months)], progression-free survival (PFS), and oneyear overall survival (1y-OS) in each cohort of advanced solid tumors.
Characterize the plasma pharmacokinetics (PK) of PM01183.
To conduct an exploratory pharmacogenomic (PGx) and pharmacogenetic analysis.
To evaluate the safety profile of PM01183 in this patient population.